伊管 ITRI 深 滬
已收盤 08-07 16:00:00 美东时间
103.75
+0.930
+0.90%
華盛通- 最 高104.06
- 今 開102.82
- 成交量 37.12万股
- 最 低 102.48
- 昨 收 102.82
- 總市值 45.43亿
- 52周最高 142.00
- 市盈率 靜 15.96
- 換手率 0.85%
- 52周最低 77.77
- 委 比 21.95%
- 總股本 4378.68万
- 歷史最高 142.00
- 量 比 0.42
- 振 幅 1.54%
- 歷史最低 26.90
- 每 手 1
- 風險率 15.84%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 最高1400美元！花旗、大小摩8家大行上调希捷科技目标价；大行集中调整目标价：康宁、科斯塔、思佳讯遭下调，PayPal、Visa、可口可乐、赛莱默获上调
今日重点评级关注：古根海姆：维持ProMIS Neurosciences"买入"评级，目标价从35美元升至69美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从38美元升至39美元
07-30 11:45
Itron Raises Profit Outlook While Revenue Growth Remains Uneven
Itron Inc. (NASDAQ:ITRI) shares traded lower on Wednesday after surging 23% to $104.51 on Tuesday. The rally followed better-than-expected second-quarter adjusted EPS and a raise of fiscal 2026 adjusted EPS guidance above estimates. The stock is trading lower after investors digest the revenue outlo...
07-29 23:43
Needham Maintains Buy on Itron, Raises Price Target to $128
Needham analyst Sean Milligan maintains Itron (NASDAQ:ITRI) with a Buy and raises the price target from $116 to $128.
07-29 18:24
美股牛股 | AI基建股IOND首日升近26%，为21年来最大直接上市项目；Lucid劲升21%
AI基建股IOND首日升近26%，为21年来最大直接上市项目；医药股PMN飙升23%，阿尔茨海默病药物试验结果积极；Lucid劲升21%，获沙特首富1.3亿美元投资>>
07-29 19:00
财报速睇 | 伊管 2026财年Q2营收5.63亿美元，同比下降7.2%；归母净利润0.53亿美元，同比下滑22.0%
华盛资讯7月29日讯，伊管公布2026财年Q2业绩，公司Q2营收5.63亿美元，同比下降7.2%，归母净利润0.53亿美元，同比下滑22.0%。
07-29 02:03
Itron shares are trading higher after the company reported better-than-expected Q2 adjusted EPS results and raised its FY26 adjusted EPS guidance above estimates.
Itron shares are trading higher after the company reported better-than-expected Q2 adjusted EPS results and raised its FY26 adjusted EPS guidance above estimates.
07-28 21:19
财报速睇 | 伊管 2026财年Q2营收5.63亿美元，同比下降7.3%；归母净利润0.53亿美元，同比下滑22.1%
华盛资讯7月28日讯，伊管公布2026财年Q2业绩，公司Q2营收5.63亿美元，同比下降7.3%，归母净利润0.53亿美元，同比下滑22.1%。
07-28 20:47
Itron Raises FY2026 Adj EPS Guidance from $5.75-$6.25 to $6.30-$6.50 vs $5.96 Est; Narrows FY2026 Sales Guidance from $2.350B-$2.450B to $2.370B-$2.410B vs $2.388B Est
Itron (NASDAQ:ITRI) raises FY2026 Adj EPS guidance from $5.75-$6.25 to $6.30-$6.50 vs $5.96 analyst estimate. Narrows FY2026 sales outlook from $2.350 billion-$2.450 billion to $2.370 billion-$2.410 billion vs $2.388 billion estimate.
07-28 20:31
Itron Sees Q3 Adj EPS $1.50-$1.60 vs $1.54 Est; Sees Sales $590.000M-$600.000M vs $607.707M Est
Itron (NASDAQ:ITRI) is looking for Q3 Adj EPS of $1.50-$1.60 vs $1.54 analyst estimate. sees sales of $590.000 million-$600.000 million vs $607.707 million analyst estimate.
07-28 20:31
Itron Q2 Adj. EPS $1.59 Beats $1.29 Estimate, Sales $562.902M Miss $566.076M Estimate
Itron (NASDAQ:ITRI) reported quarterly earnings of $1.59 per share which beat the analyst consensus estimate of $1.29 by 23.26 percent. This is a 1.85 percent decrease over earnings of $1.62 per share from the same period last year. The company reported quarterly sales of $562.902 million which miss...
07-28 20:31
